GoodRx Holdings, Inc. (NASDAQ:GDRX) Major Shareholder Sells $43,668.93 in Stock

GoodRx Holdings, Inc. (NASDAQ:GDRX) major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the business’s stock in a transaction on Friday, June 6th. The stock was sold at an average price of $4.09, for a total value of $43,668.93. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

GoodRx Trading Up 10.5%

NASDAQ:GDRX opened at $4.54 on Wednesday. GoodRx Holdings, Inc. has a 1 year low of $3.68 and a 1 year high of $9.26. The stock’s fifty day moving average price is $4.25 and its two-hundred day moving average price is $4.53. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The company has a market cap of $1.62 billion, a P/E ratio of -151.33, a P/E/G ratio of 2.46 and a beta of 1.16.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.05. GoodRx had a positive return on equity of 5.35% and a negative net margin of 2.05%. The company had revenue of $202.97 million for the quarter, compared to analyst estimates of $202.25 million. During the same period in the previous year, the company posted $0.08 EPS. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. As a group, analysts expect that GoodRx Holdings, Inc. will post 0.13 EPS for the current year.

Hedge Funds Weigh In On GoodRx

A number of large investors have recently modified their holdings of the company. Jane Street Group LLC purchased a new stake in GoodRx in the 1st quarter worth approximately $370,000. Goldman Sachs Group Inc. increased its holdings in shares of GoodRx by 7.5% in the first quarter. Goldman Sachs Group Inc. now owns 783,378 shares of the company’s stock worth $3,455,000 after purchasing an additional 54,783 shares during the period. Petrus Trust Company LTA raised its position in shares of GoodRx by 7.4% in the first quarter. Petrus Trust Company LTA now owns 3,167,015 shares of the company’s stock worth $13,967,000 after buying an additional 216,926 shares in the last quarter. AQR Capital Management LLC boosted its stake in GoodRx by 124.4% during the first quarter. AQR Capital Management LLC now owns 282,320 shares of the company’s stock valued at $1,245,000 after buying an additional 156,482 shares during the period. Finally, EP Wealth Advisors LLC bought a new stake in GoodRx during the first quarter valued at $69,000. 63.77% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. UBS Group lowered their price objective on shares of GoodRx from $6.00 to $5.25 and set a “neutral” rating on the stock in a research report on Tuesday, May 13th. Truist Financial lowered their price target on shares of GoodRx from $6.50 to $5.50 and set a “hold” rating on the stock in a report on Thursday, April 10th. The Goldman Sachs Group dropped their price objective on GoodRx from $6.00 to $5.00 and set a “neutral” rating on the stock in a research note on Friday, May 9th. Finally, Wells Fargo & Company decreased their target price on GoodRx from $8.00 to $7.00 and set an “overweight” rating for the company in a research report on Tuesday, April 29th. Five equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $6.55.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.